AMERICAN JOINT COMMITTEE ON CANCER

美国癌症联合委员会

• 批准号: 3163497
• 负责人: OLIVER H BEAHRS
• 金额: $ 1.78万
• 依托单位: AMERICAN COLLEGE OF SURGEONS
• 依托单位国家: 美国
• 财政年份: 1980
• 资助国家: 美国
• 起止时间: 1980-03-01 至 1990-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3163497
• 关键词: Hodgkin's disease; bladder neoplasm; bone neoplasms; brain neoplasms; breast neoplasms; cancer information system; cancer registry /resource; data collection; female reproductive system neoplasm; information dissemination; information retrieval; medical records; melanoma; neoplasm /cancer classification /staging; neoplasm /cancer diagnosis; neoplasm /cancer epidemiology; nose neoplasm; ovary neoplasms; pancreatic islet neoplasm; prognosis; prostate neoplasms; rectum neoplasms; salivary gland neoplasms; statistics /biometry; testis neoplasms; thyroid neoplasm; urinary tract neoplasms; vagina

The American Joint Committee has been engaged in a clinical research project to develop staging classifications for cancer of all anatomic sites. During the past year following considerable thought as to the future activities of the AJC, the following plan has resulted: 1) To complete classifications where further work is needed: bone, central nervous system, melanoma, and GU malignancies; (2) To encourage the use of classification for staging in end results reporting, reporting to journals, libraries, cancer registries, and medical societies; 3) To work with groups on a national level who are doing cancer staging, i.e., SEER, CCPDS, CICA, ACCC, ACOS, and other central and hospital registries, to develop a common computer code; (4) To further refine, publicize, distribute and encourage use of specific site cancer data collection forms; 5) To test the validity of the classifications, with data from SEER and other groups; 6) To evaluate biological markers and other factors which are important in classification of specific cancers and their prognoses, and to determine their relative importance; 7) To evaluate the relative importance and cost effectiveness of various tests and procedures utilized in pretreatment clinical staging and in posttreatment follow-up evaluations, in an effort to discourage over-utilization of expensive tests which are rarely positive and add little to management.

美国联合委员会一直在从事一项临床研究项目， 为所有解剖部位的癌症制定分期分类。 期间 在对犹太委员会今后的活动进行了大量思考之后， 已制定了以下计划：1）完成分类， 需要开展的工作：骨、中枢神经系统、黑色素瘤和GU恶性肿瘤; (2)为鼓励在最终成果报告中使用分类进行阶段划分， 向期刊、图书馆、癌症登记处和医学协会报告; 3） 与国家一级的癌症分期小组合作，即， SEER、CCPDS、CICA、ACCC、ACOS和其他中心和医院登记， （4）进一步完善、宣传、分发和 鼓励使用特定部位癌症数据收集表; 5）测试 分类的有效性，使用SEER和其他团体的数据; 6） 评估生物标志物和其他重要因素， 特定癌症及其并发症的分类，并确定其 相对重要性; 7）评估相对重要性和成本 治疗前临床使用的各种检查和程序的有效性 分期和治疗后随访评估，以努力阻止 过度使用昂贵的测试，这些测试很少是积极的， 管理